Genmab (Otc) (GMAB) has released an update.
Genmab A/S successfully completed its share buy-back program on March 15, 2024, fulfilling its commitment to the Restricted Stock Units program. The biotech company repurchased a total of 190,000 shares, now holding 865,972 treasury shares, which equates to 1.31% of its total share capital and voting rights. The buy-back, conducted under EU Market Abuse Regulation and Safe Harbour Regulation, underscores Genmab’s dedication to its long-term vision of transforming lives with innovative antibody medicines.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
